CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane Meeting Abstract
| Authors: | Schwartzberg, L.; Asselah, J.; Bondarenko, I.; Chae, Y.; DaCosta, N.; Feng, Y. H.; Izarzugaza, Y.; Lemieux, J.; Liu, M. C.; Marx, G.; O'Shaughnessy, J.; Oliveira, M.; Rugo, H.; Seidman, A.; Wright, G.; O'Connell, J.; Wei, T.; Kim, S. B. |
| Abstract Title: | CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012500102 |
| DOI: | 10.1158/1538-7445.Sabcs19-ot1-08-07 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: OT1-08-07 -- Source: Wos |
